Stem cell grafts - Miltenyi BiotechAlternative Names: TCRabCD19PBSC
Latest Information Update: 02 Feb 2017
At a glance
- Originator Miltenyi Biotec GmbH
- Class Stem cell therapies
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Cancer; Haematological disorders; Immunodeficiency disorders; Metabolic disorders